The serine phosphorylations in the IRS-1 PIR domain abrogate IRS-1 and IR interaction
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2401716121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Ju Rang Woo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Convergence Technology, New Drug Development Center, KBIOHealth, Cheongju 28160, Republic of Korea. Hauptthemen laut MEDLINE: Insulin Resistance, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
Serine phosphorylations on insulin receptor substrate 1 (IRS-1) by diverse kinases aoccur widely during obesity-, stress-, and inflammation-induced conditions in models of insulin resistance and type 2 diabetes. In this study, we define a region within the human IRS-1, which is directly C-terminal to the PTB domain encompassing numerous serine phosphorylation sites including Ser307 (mouse Ser302) and Ser312 (mouse 307) creating a phosphorylation insulin resistance (PIR) domain. We demonstrate that the IRS-1 PTB-PIR with its unphosphorylated serine residues interacts with the insulin receptor (IR) but loses the IR-binding when they are phosphorylated. Surface plasmon resonance studies further confirm that the PTB-PIR binds stronger to IR than just the PTB domain, and that phosphorylations at Ser307, Ser312, Ser315, and Ser323 within the PIR domain result in abrogating the binding. Insulin-responsive cells containing the mutant IRS-1 with all these four serines changed into glutamates to mimic phosphorylations show decreased levels of phosphorylations in IR, IRS-1, and AKT compared to the wild-type IRS-1. Hydrogen–deuterium exchange mass spectrometry experiments indicating the PIR domain interacting with the N-terminal lobe and the hinge regions of the IR kinase domain further suggest the possibility that the IRS-1 PIR domain protects the IR from the PTP1B-mediated dephosphorylation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Convergence Technology, New Drug Development Center, KBIOHealth, Cheongju 28160, Republic of Korea.
- Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang 10408, Republic of Korea.
- Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang 10408, Republic of Korea.
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115.
- Soonchunhyang Institute of Medi-Bio Science, Soonchunhyang University, Cheonan 31151, Republic of Korea.
- School of Systems Biomedical Science, Soongsil University, Seoul 06978, Republic of Korea.
ORCID-Profile: Seung-Hyun Bae, John R Engen, Jongsoon Lee, Hyonchol Jang
Förderung
- National Research Foundation of Korea (NRF)
Zitieren
APA
Woo, J. R., Bae, S. H., Wales, T. E., Engen, J. R., Lee, J., Jang, H., & Park, S. (2024). The serine phosphorylations in the IRS-1 PIR domain abrogate IRS-1 and IR interaction. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2401716121
Vancouver
Woo JR, Bae SH, Wales TE, Engen JR, Lee J, Jang H, et al. The serine phosphorylations in the IRS-1 PIR domain abrogate IRS-1 and IR interaction. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2401716121
BibTeX
@article{Woo2024,
author = {Woo, Ju Rang and Bae, Seung-Hyun and Wales, Thomas E and Engen, John R and Lee, Jongsoon and Jang, Hyonchol and Park, SangYoun},
title = {The serine phosphorylations in the IRS-1 PIR domain abrogate IRS-1 and IR interaction},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2401716121}
}
EUVIMED